[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse PLAUR

Summary
SymbolPLAUR
Nameplasminogen activator, urokinase receptor
Aliases URKR; UPAR; CD87; urokinase-type plasminogen activator (uPA) receptor; urokinase plasminogen activator surfa ......
Chromosomal Location19q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Cell projection, invadopodium membrane Note=Colocalized with FAP (seprase) preferentially at the cell surface of invadopodia membrane in a cytoskeleton-, integrin- and vitronectin-dependent manner. ; SUBCELLULAR LOCATION: Isoform 1: Cell membrane Lipid-anchor, GPI-anchor ; SUBCELLULAR LOCATION: Isoform 2: Secreted
Domain PF00021 u-PAR/Ly-6 domain
Function

Acts as a receptor for urokinase plasminogen activator. Plays a role in localizing and promoting plasmin formation. Mediates the proteolysis-independent signal transduction activation effects of U-PA. It is subject to negative-feedback regulation by U-PA which cleaves it into an inactive form.

> Gene Ontology
 
Biological Process GO:0001836 release of cytochrome c from mitochondria
GO:0006497 protein lipidation
GO:0006505 GPI anchor metabolic process
GO:0006506 GPI anchor biosynthetic process
GO:0006643 membrane lipid metabolic process
GO:0006644 phospholipid metabolic process
GO:0006650 glycerophospholipid metabolic process
GO:0006661 phosphatidylinositol biosynthetic process
GO:0006664 glycolipid metabolic process
GO:0007173 epidermal growth factor receptor signaling pathway
GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0008637 apoptotic mitochondrial changes
GO:0008654 phospholipid biosynthetic process
GO:0009247 glycolipid biosynthetic process
GO:0010466 negative regulation of peptidase activity
GO:0010821 regulation of mitochondrion organization
GO:0010822 positive regulation of mitochondrion organization
GO:0010951 negative regulation of endopeptidase activity
GO:0016255 attachment of GPI anchor to protein
GO:0030193 regulation of blood coagulation
GO:0030195 negative regulation of blood coagulation
GO:0032102 negative regulation of response to external stimulus
GO:0038127 ERBB signaling pathway
GO:0038195 urokinase plasminogen activator signaling pathway
GO:0042058 regulation of epidermal growth factor receptor signaling pathway
GO:0042157 lipoprotein metabolic process
GO:0042158 lipoprotein biosynthetic process
GO:0042730 fibrinolysis
GO:0043154 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043281 regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043388 positive regulation of DNA binding
GO:0045017 glycerolipid biosynthetic process
GO:0045742 positive regulation of epidermal growth factor receptor signaling pathway
GO:0045861 negative regulation of proteolysis
GO:0046467 membrane lipid biosynthetic process
GO:0046474 glycerophospholipid biosynthetic process
GO:0046486 glycerolipid metabolic process
GO:0046488 phosphatidylinositol metabolic process
GO:0050817 coagulation
GO:0050818 regulation of coagulation
GO:0050819 negative regulation of coagulation
GO:0050878 regulation of body fluid levels
GO:0051098 regulation of binding
GO:0051099 positive regulation of binding
GO:0051101 regulation of DNA binding
GO:0051346 negative regulation of hydrolase activity
GO:0052547 regulation of peptidase activity
GO:0052548 regulation of endopeptidase activity
GO:0061041 regulation of wound healing
GO:0061045 negative regulation of wound healing
GO:0090199 regulation of release of cytochrome c from mitochondria
GO:0090200 positive regulation of release of cytochrome c from mitochondria
GO:0097193 intrinsic apoptotic signaling pathway
GO:1900046 regulation of hemostasis
GO:1900047 negative regulation of hemostasis
GO:1901184 regulation of ERBB signaling pathway
GO:1901186 positive regulation of ERBB signaling pathway
GO:1902532 negative regulation of intracellular signal transduction
GO:1903034 regulation of response to wounding
GO:1903035 negative regulation of response to wounding
GO:1903509 liposaccharide metabolic process
GO:2000116 regulation of cysteine-type endopeptidase activity
GO:2000117 negative regulation of cysteine-type endopeptidase activity
GO:2001233 regulation of apoptotic signaling pathway
GO:2001234 negative regulation of apoptotic signaling pathway
GO:2001235 positive regulation of apoptotic signaling pathway
GO:2001242 regulation of intrinsic apoptotic signaling pathway
GO:2001243 negative regulation of intrinsic apoptotic signaling pathway
GO:2001267 regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway
GO:2001268 negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway
Molecular Function GO:0030377 urokinase plasminogen activator receptor activity
Cellular Component GO:0005788 endoplasmic reticulum lumen
GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0019898 extrinsic component of membrane
GO:0030055 cell-substrate junction
GO:0031225 anchored component of membrane
GO:0031253 cell projection membrane
GO:0071437 invadopodium
GO:0071438 invadopodium membrane
> KEGG and Reactome Pathway
 
KEGG hsa04610 Complement and coagulation cascades
Reactome R-HSA-162791: Attachment of GPI anchor to uPAR
R-HSA-75205: Dissolution of Fibrin Clot
R-HSA-109582: Hemostasis
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-392499: Metabolism of proteins
R-HSA-6798695: Neutrophil degranulation
R-HSA-163125: Post-translational modification
R-HSA-597592: Post-translational protein modification
Summary
SymbolPLAUR
Nameplasminogen activator, urokinase receptor
Aliases URKR; UPAR; CD87; urokinase-type plasminogen activator (uPA) receptor; urokinase plasminogen activator surfa ......
Chromosomal Location19q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PLAUR and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between PLAUR and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26879524MelanomaInhibit immunityHerein, we report the first antibody-recruiting small molecule (ARM) that is capable of recognizing the urokinase-type plasminogen activator receptor (uPAR), a uniquely overexpressed cancer cell-surface marker, and facilitating the immune-mediated destruction of cancer cells.
Summary
SymbolPLAUR
Nameplasminogen activator, urokinase receptor
Aliases URKR; UPAR; CD87; urokinase-type plasminogen activator (uPA) receptor; urokinase plasminogen activator surfa ......
Chromosomal Location19q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PLAUR in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPLAUR
Nameplasminogen activator, urokinase receptor
Aliases URKR; UPAR; CD87; urokinase-type plasminogen activator (uPA) receptor; urokinase plasminogen activator surfa ......
Chromosomal Location19q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PLAUR in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.3960.0318
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.380.582
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-1.3830.364
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.4770.345
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.5710.771
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.3520.893
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2280.714
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.640.667
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2370.883
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5940.726
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.0650.667
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1970.254
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PLAUR in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPLAUR
Nameplasminogen activator, urokinase receptor
Aliases URKR; UPAR; CD87; urokinase-type plasminogen activator (uPA) receptor; urokinase plasminogen activator surfa ......
Chromosomal Location19q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PLAUR. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPLAUR
Nameplasminogen activator, urokinase receptor
Aliases URKR; UPAR; CD87; urokinase-type plasminogen activator (uPA) receptor; urokinase plasminogen activator surfa ......
Chromosomal Location19q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PLAUR. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PLAUR.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPLAUR
Nameplasminogen activator, urokinase receptor
Aliases URKR; UPAR; CD87; urokinase-type plasminogen activator (uPA) receptor; urokinase plasminogen activator surfa ......
Chromosomal Location19q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PLAUR. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPLAUR
Nameplasminogen activator, urokinase receptor
Aliases URKR; UPAR; CD87; urokinase-type plasminogen activator (uPA) receptor; urokinase plasminogen activator surfa ......
Chromosomal Location19q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PLAUR expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPLAUR
Nameplasminogen activator, urokinase receptor
Aliases URKR; UPAR; CD87; urokinase-type plasminogen activator (uPA) receptor; urokinase plasminogen activator surfa ......
Chromosomal Location19q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PLAUR and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPLAUR
Nameplasminogen activator, urokinase receptor
Aliases URKR; UPAR; CD87; urokinase-type plasminogen activator (uPA) receptor; urokinase plasminogen activator surfa ......
Chromosomal Location19q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PLAUR collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting PLAUR.
ID Name Drug Type Targets #Targets
DB00009AlteplaseBiotechFGA, PLAUR, PLG, SERPINE14
DB00013UrokinaseBiotechLRP2, NID1, PLAT, PLAU, PLAUR, PLG, SERPINA5, SERPINB2, SERPINE1, ......10
DB00015ReteplaseBiotechFGA, PLAUR, PLG, SERPINE14
DB00029AnistreplaseBiotechFGA, PLAUR, PLG, SERPINE14
DB00031TenecteplaseBiotechANXA2, CALR, CANX, CLEC3B, FGA, KRT8, LRP1, PLAUR, PLG, SERPINB2, ......11
DB05476WX-UK1Small MoleculePLAUR1
DB06245LanoteplaseBiotechANXA2, CALR, CANX, CLEC3B, F10, FGA, FN1, KLK1, KRT8, LAMA1, LAMA3 ......17